| Extensive research has uncovered a set of molecular surveillance mechanisms commonly called checkpoints which tightly monitor cell-cycle processes. Today s anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets. Research now promises to uncover a new generation of anticancer drugs with improved therapeutic indices based on their ability to target emerging checkpoint components. Checkpoint Responses in Cancer Therapy summarizes the advances made over the past 20 years, identifying components of cell-cycle checkpoints and their molecular regulation during checkpoint activation and validating the use of checkpoint proteins as targets for the development of anticancer drugs. This book s distinguished panel of authors takes a close look at topics ranging from the major molecular players affecting DNA synthesis and the response to DNA damage to advances made in the identification of chemical compounds capable of inhibiting individual mitotic kinases. Illuminating and authoritative, Checkpoint Responses in Cancer Therapy offers a critical summary of findings for researchers in the pharmaceutical and biotechnology industries and a valuable resource for academic scientists in cancer research and the study of cell-cycle regulation, signal transduction and apoptosis. |
|
| |
| Binding: Hardcover |
| Specs: 314 pages | 1.5 Lbs |
| ISBN: 1588299309 |
| ISBN-13: 9781588299307 |
| Edition: 1 |
| Publisher: Humana Press | Publish Date 06/08 | Copyright 2008 |
| Series: Cancer Drug Discovery and Development |
Table Of Contents:
RB-pathway : cell cycle control and cancer therapy
Erik S. Knudsen, Wesley A. Braden
Targeting the P53/MDM2 pathway for cancer therapy
Christian Klein, Lyubomir T. Vassilev
DNA topoisomerases as targets for the chemotherapeutic treatment of cancer
Ryan P. Bender, Neil Osheroff
Targeting ATM/ATR in the DNA damage checkpoint
Joseph M. Ackermann, Wafik S. El-Deiry
Compounds that abrogate the G2 checkpoint
Takumi Kawabe
CDK inhibitors as anticancer agents
Timothy A. Yap, L. Rhoda Molife, Johann S. de Bono
CHFR as a potential anticancer target
Minoru Toyota, Lisa Kashima, Takashi Tokino
Antimicrotube agents
Miguel A. Villalona-Calero, Larry Schaaf, Robert Turowski
Kinesin motor inhibitors as effective anticancer drugs
Vasiliki Sarli, Athanassios Giannis
Targeting the spindle checkpoint in cancer chemotherapy
Jungseog Kang, Hongtao Yu
Antiproliferation inhibitors targeting aurora kinases
Kishore Shakalya, Daruka Mahadevan
P1ks as novel targets for cancer drug design
Wei Dai, Yali Yang, Ning Jiang
Do histone deacetylase inhibitors target cell cycle checkpoints that monitor heterochromatin structure?
Brian Gabrielli, Frankie Stevens, Heather Beamish
Index |
| |
|
| |
|
|
|